Shares of The Medicines Company (MDCO +1.7%) move up after being initiated with an Outperform at...

|About: The Medicines Company (MDCO)|By:, SA News Editor

Shares of The Medicines Company (MDCO +1.7%) move up after being initiated with an Outperform at Oppenheimer. The firm says that the Street has all but ignored MDCO's strong pipeline, noting that Angiomax, its key asset, is worth around $19 per share as a stand alone product. Additionally, Phase III data from its antiplatelet-agent Cangrelor is due by early 2013 at the latest, and results from two Phase III studies of its antibiotic treatment Oritavancin should come some time in the first half of next year as well.